Hanmi Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Hanmi Pharm makes prescription medicines for conditions such as high blood pressure, high cholesterol, acid reflux, and erectile dysfunction, and supplies them to patients and healthcare providers in South Korea and internationally.
Its subsidiary Hanmi Jeongmil Hwahak produces active pharmaceutical ingredients, the raw chemical compounds used to manufacture finished drugs, and exports them to over forty countries, including to multinational pharmaceutical companies. Listed on the KOSPI, South Korea's main stock exchange, the company operates across three distinct segments: domestic pharmaceuticals, active ingredients, and an overseas pharmaceutical business based in China.
Summary is AI-generated and may contain errors · figures from DART filings
Its China-based subsidiary, Beijing Hanmi Pharmaceutical Co., Ltd., was established by Hanmi Pharm and operates as an independent pharmaceutical company handling its own research, manufacturing, and sales.
Hanmi Pharm in five facts
What does Hanmi Pharm do?
Hanmi Pharm makes prescription medicines for conditions such as high blood pressure, high cholesterol, acid reflux, and erectile dysfunction, and supplies them to patients and healthcare providers in South Korea and internationally.
Where is Hanmi Pharm listed and in which sector?
Hanmi Pharm (Korean name: 한미약품) trades under KRX code 128940 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Hanmi Pharm?
Its market capitalisation was US$3.7B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Hanmi Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Hanmi Pharm reported revenue of US$1.2B, operating profit of US$194.6M and net income of US$141.2M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 3.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meeting (notice)Oct 16
- Earnings release schedule notice (notice)Oct 16
- DisclosureOct 7
- Report on securities held by executives/major shareholdersOct 6
- Report on large shareholdings (5% rule) (abbreviated)Oct 2
- Material management matter relevant to investment decisionsSep 29
- Report on large shareholdings (5% rule) (standard)Sep 29
- Report on securities held by executives/major shareholdersSep 29
- Investor relations (IR) meeting (notice)Sep 8
- Change in shares held by the largest shareholderSep 8
- Report on large shareholdings (5% rule) (standard)Sep 8
- Treasury share disposal: results report
Hanmi Pharm Co., Ltd. completed disposal of 11,180 treasury common shares to officers and employees on August 4, 2026 for US$2.72M (US$242.92 per share), following its July 28, 2026 material event report; the actual number disposed differed slightly from the planned 10,402 shares due to share price and performance-evaluation changes.
Treasury Shares · Aug 7 - Operating results (consolidated) (preliminary) (fair disclosure)
Hanmi Pharm filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$322M (+29.3% year on year), operating profit of US$90.2M (+116.9% year on year) and net income of US$57.9M (+95.5% year on year).
Earnings · Jul 28 - Material event report (treasury share disposal)
Hanmi Pharm disclosed a plan to sell treasury shares worth US$2.8M, about 0.1% of its market value.
Treasury Shares · Jul 28 - Supply contract signed
Hanmi Pharm disclosed a supply contract with Organon International GmbH, worth US$35.1M, about 3.4% of its recent annual revenue, running through May 2036.
Supply contract · May 21 - Operating results (consolidated) (preliminary) (fair disclosure)
Hanmi Pharm filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$267M (+0.5% year on year), operating profit of US$36.4M (−9.1% year on year) and net income of US$34.7M (+14.4% year on year).
Earnings · Apr 30 - Cash/in-kind dividend decision
Hanmi Pharm declared a cash dividend of US$1.36 per share, equal to about 0.4% of the recent share price.
Dividend · Mar 12 - Treasury share disposal: results reportTreasury Shares · Feb 13
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Hanmi Pharm reported consolidated results for FY2025: revenue of US$1.06B (+3.48% year on year), operating profit of US$177M (+19.25% year on year) and net income of US$129M (+33.92% year on year).
Earnings · Feb 5 - Operating results (consolidated) (preliminary) (fair disclosure)
Hanmi Pharm filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$297M (+23.14% year on year), operating profit of US$57M (+173.42% year on year) and net income of US$37.7M (from a loss a year earlier).
Earnings · Feb 5 - Supply contract signedSupply contract · Jan 28
- Material event report (treasury share disposal)Treasury Shares · Jan 9